Your browser is no longer supported. Please, upgrade your browser.
ADXS Advaxis, Inc. daily Stock Chart
Advaxis, Inc.
Index- P/E- EPS (ttm)-7.31 Insider Own0.10% Shs Outstand17.53M Perf Week-0.64%
Market Cap7.05M Forward P/E- EPS next Y-2.24 Insider Trans20.65% Shs Float16.94M Perf Month-40.37%
Income-29.20M PEG- EPS next Q-1.32 Inst Own14.30% Short Float3.92% Perf Quarter-86.32%
Sales23.10M P/S0.31 EPS this Y44.00% Inst Trans80.63% Short Ratio1.29 Perf Half Y-92.94%
Book/sh7.32 P/B0.05 EPS next Y62.40% ROA-52.20% Target Price9.65 Perf Year-98.18%
Cash/sh- P/C- EPS next 5Y- ROE-84.60% 52W Range0.36 - 23.70 Perf YTD-85.89%
Dividend- P/FCF- EPS past 5Y20.60% ROI-292.20% 52W High-98.30% Beta3.15
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low13.24% ATR0.08
Employees58 Current Ratio7.10 Sales Q/Q-29.40% Oper. Margin- RSI (14)21.18 Volatility11.29% 12.12%
OptionableYes Debt/Eq0.00 EPS Q/Q60.60% Profit Margin- Rel Volume0.88 Prev Close0.42
ShortableYes LT Debt/Eq0.00 EarningsSep 09 AMC Payout- Avg Volume515.63K Price0.40
Recom2.50 SMA20-13.88% SMA50-67.93% SMA200-89.98% Volume454,360 Change-4.26%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Aug-22-19 08:00AM  Advaxis, Inc. Issues Letter to Shareholders Business Wire
Aug-12-19 06:30AM  BriaCell Appoints Richard J. Berman to Board of Directors GlobeNewswire
Jul-25-19 11:30AM  Advaxis, Inc. Announces Closing of $17 Million Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option Business Wire -12.43%
Jul-24-19 07:08AM  The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index Benzinga +10.00%
Jul-23-19 08:30AM  Advaxis, Inc. Announces Pricing of $16 Million Public Offering Business Wire -23.91%
Jul-15-19 08:00AM  New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies Business Wire
Jun-27-19 06:50AM  Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study Business Wire -6.67%
Jun-21-19 10:14AM  Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT Thomson Reuters StreetEvents
Jun-11-19 09:00AM  Advaxis, Inc. to Host Earnings Call ACCESSWIRE -8.21%
Jun-10-19 04:05PM  Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update Business Wire
Jun-04-19 08:00AM  Advaxis to Host Business Update Conference Call on June 11, 2019 Business Wire +8.24%
May-25-19 09:48AM  What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)? Simply Wall St.
May-15-19 10:25AM  Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug Benzinga
08:00AM  FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac Business Wire
May-14-19 09:00AM  Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference Business Wire
May-13-19 03:00PM  Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer Business Wire -7.40%
May-07-19 09:00AM  Advaxis to Participate in Five Upcoming Industry Conferences Business Wire
Apr-18-19 05:45PM  Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know Zacks
Apr-16-19 10:54AM  QIAGEN Drives Molecular Diagnostics Suite With New Test Kit Zacks
Apr-10-19 08:43AM  Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session Zacks
Apr-08-19 09:30AM  Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year? Zacks
Apr-03-19 04:31PM  Why Range Resources, Advaxis, and StoneCo Slumped Today Motley Fool -31.36%
08:19AM  The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
07:44AM  Advaxis' stock plummets after public offering prices at deep discount MarketWatch
07:30AM  Advaxis Announces Pricing of Its Public Offering of Common Stock Business Wire
Apr-02-19 04:05PM  Advaxis, Inc. Announces Proposed Public Offering of Common Stock Business Wire -9.37%
09:44AM  Advaxis Up on Positive Early-Stage Immunotherapy Study Data Zacks
Apr-01-19 04:31PM  Why Wynn Resorts, Advaxis, and Roku Jumped Today Motley Fool +10.15%
03:18PM  Why Advaxis Stock Skyrocketed 13.8% Today Motley Fool
02:27PM  Advaxis Shares Surge After Positive Clinical Trial Updates Benzinga
12:20PM  Reverse Split and New Clinical Data, What's Next for Advaxis? ACCESSWIRE
12:11PM  Biotech News: Why Advaxis Stock Is Soaring Today InvestorPlace
08:00AM  ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer Business Wire
Mar-30-19 09:32AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
Mar-29-19 03:00PM  Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity Business Wire
Mar-28-19 01:00PM  Advaxis Announces Reverse Stock Split Business Wire -14.54%
10:41AM  Top Ranked Momentum Stocks to Buy for March 28th Zacks
Mar-27-19 10:54AM  Top Ranked Momentum Stocks to Buy for March 27th Zacks -6.15%
Mar-25-19 09:25AM  Top Ranked Momentum Stocks to Buy for March 25th Zacks +5.00%
08:00AM  Advaxis Granted U.S. Patent Relating to Axalimogene Filolisbac Business Wire
Mar-22-19 09:30AM  Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year? Zacks
Mar-13-19 03:00PM  These Four Healthcare Stocks Are Making Moves on Wednesday ACCESSWIRE +22.64%
08:45AM  Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher Zacks
Mar-12-19 08:13AM  Advaxis: Fiscal 1Q Earnings Snapshot Associated Press +23.92%
08:00AM  Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update Business Wire
Mar-11-19 08:00AM  Advaxis Announces Presentations of ADXS-NEO and ADXS-PSA Data at Upcoming American Association for Cancer Research Annual Meeting Business Wire
Feb-20-19 10:51AM  Advaxis (ADXS) Upgraded to Buy: Here's What You Should Know Zacks
Feb-14-19 08:30AM  Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer Business Wire
Feb-12-19 01:10PM  How Financially Strong Is Advaxis, Inc. (NASDAQ:ADXS)? Simply Wall St.
Feb-06-19 08:30AM  Advaxis Presents an Overview of its Lm Platform and Neoantigen-Directed Programs at the Immuno-Oncology 360° Conference Business Wire +20.05%
Jan-31-19 12:34PM  Edited Transcript of ADXS earnings conference call or presentation 15-Jan-19 4:00pm GMT Thomson Reuters StreetEvents +11.44%
Jan-30-19 07:35AM  New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire -5.53%
Jan-28-19 08:05AM  Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference Business Wire
Jan-25-19 08:05AM  Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines Business Wire +17.46%
Jan-24-19 10:00AM  Immunomodulation Bolsters Scientific Advisory Board with Appointments of Robert G. Petit, Ph.D. and Rex Chin-Wei Yung, M.D., F.C.C.P. GlobeNewswire
07:45AM  The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial Benzinga
Jan-23-19 04:05PM  Advaxis Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests Business Wire -10.09%
Jan-11-19 08:38AM  The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga -15.56%
Jan-10-19 05:25PM  Advaxis (ADXS) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM  Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update Business Wire
Jan-08-19 08:00AM  Advaxis to Host Business Update Conference Call on January 15, 2019 Business Wire -15.11%
Dec-12-18 10:30AM  Will Advaxis (ADXS) Report Negative Earnings Next Week? What You Should Know Zacks
08:59AM  Could Advaxis, Inc.s (NASDAQ:ADXS) Investor Composition Influence The Stock Price? Simply Wall St.
Nov-28-18 08:00AM  Advaxis to Present at LD Micro Main Event Business Wire +6.16%
Nov-06-18 08:00AM  Advaxis to Present Poster Entitled Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy at Society for Immunotherapy of Cancer Annual Meeting Business Wire +9.19%
Nov-02-18 08:00AM  Advaxis Provides Update on Clinical Pipeline Business Wire
Oct-26-18 08:00AM  Advaxis to Host Business Update Conference Call on November 2, 2018 Business Wire +10.22%
Oct-18-18 09:25AM  Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Sep-25-18 08:00AM  Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-12-18 08:26AM  The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt Benzinga
Sep-11-18 12:00PM  Advaxis Inc (NASDAQ:ADXS): How Much Growth Is Left In Healthcare? Simply Wall St. -11.09%
09:20AM  Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants Business Wire
08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
Sep-10-18 04:35PM  Advaxis: Fiscal 3Q Earnings Snapshot Associated Press -6.25%
04:30PM  Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results Business Wire
Sep-07-18 09:25AM  Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants Business Wire -28.67%
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
Sep-06-18 05:08PM  Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants Business Wire -5.92%
Sep-04-18 08:00AM  Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma Business Wire
Aug-28-18 07:45AM  Recent Analysis Shows Liberty TripAdvisor, Control4, Ferro, Advaxis, Frontier Communications, and Newpark Resources Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-30-18 08:00AM  Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer Business Wire
Jul-26-18 07:20AM  Free Technical Research on Advaxis and Three More Biotech Equities ACCESSWIRE -6.67%
Jul-18-18 08:08AM  Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates Zacks
Jul-17-18 07:10AM  Blog Exposure - FDA Lifts Clinical Hold on Advaxis' Cancer Drug ACCESSWIRE
Jul-16-18 10:45AM  Biotech Companies with Great Futures ACCESSWIRE +7.46%
Jul-13-18 11:37AM  Advaxis Shares Soar After FDA Lifts Clinical Hold On Cancer Drug Benzinga +9.84%
08:18AM  Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial MarketWatch
08:00AM  Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab Business Wire
Jul-10-18 08:00AM  Advaxis Provides Update on MAA Filing and ADXS-HOT Program Business Wire -8.28%
Jun-28-18 08:15AM  New Research Coverage Highlights Knowles, Advaxis, G-III Apparel Group, LTD, National CineMedia, Haemonetics, and MACOM Technology Solutions Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jun-18-18 12:18PM  Edited Transcript of ADXS earnings conference call or presentation 7-Jun-18 3:00pm GMT Thomson Reuters StreetEvents
Jun-11-18 08:00AM  Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens Business Wire
Jun-07-18 09:25AM  Advaxis: Fiscal 2Q Earnings Snapshot Associated Press +11.11%
09:05AM  Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results Business Wire
07:45AM  Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 08:00AM  Advaxis Appoints Molly Henderson as Chief Financial Officer Business Wire
Jun-01-18 08:00AM  Data Highlighting Advaxis ADXS-PSA Presented at ASCO Annual Meeting Business Wire
May-31-18 08:00AM  Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018 Business Wire
May-14-18 08:10AM  Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.62%
May-11-18 08:00AM  Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent Business Wire +8.54%
Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
APPEL RONIDirectorApr 10Buy3.803,00011,39113,476Apr 11 12:11 PM
PETIT ROBERTChief Scientific OfficerNov 05Sale0.583,9632,299231,206Nov 07 05:00 PM
PETIT ROBERTChief Scientific OfficerNov 02Sale0.568,4914,755235,169Nov 05 06:00 PM
APPEL RONIDirectorSep 11Buy1.2033,33340,000157,143Sep 13 04:30 PM